[Clinical trial of Trental 100 in patients with peripheral arterial occlusive diseases (author's transl)].
The preparation Trental 100 was given to 73 patients in a vascular surgery department at a daily dose of 2-3 dragees over an average of 2-3 months. 51 of 67 patients with chronic arterial disorders of the lower extremities and 5 of 6 patients with circulatory disturbances in the brachial region improved, as measured by the walking distance, reactive hyperemia time, pain at rest and effect in tissue defects. Tests for objective tolerance showed no effects on the blood picture, liver and kidney functions and carbohydrate metabolism. In a few patients, subjective intolerance disappeared after reducing the dose.
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001769:Blood / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D005684:Gait; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*
D013805:Theobromine; D010431:Pentoxifylline
Zur klinischen Erprobung von Trental 100 bei Gefässkranken mit peripherer arterieller Verschlusskrankheit.